GlassScriptPhysician profile
Nelson Negron
NPI 1447838933
$3,566.63
in general payments reported to CMS, 2019-2025
13 companies · $1,120 in 2025
The $1,120 reported for 2025 was more than what 87% of Foot Surgery providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,447 · 2025: $1,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,951 · Travel and Lodging: $1,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,950.64 |
| Travel and Lodging | $1,615.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $2,957.16 | 2024-2025 | Ortholoc 3di, Ortholoc 2 Lapifuse, Augment Injectable |
| Smith+Nephew, INC. | $202.76 | 2024-2025 | Grafix Pl, Renasys Touch, Iodosorb Ointment 40g USA |
| Tactile Systems Technology INC | $67.25 | 2024-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Paratek Pharmaceuticals, INC. | $62.46 | 2024 | Nuzyra |
| Kerecis Limited | $49.78 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Organogenesis INC. | $44.87 | 2025 | Puraply Wound Matrix, Apligraf |
| Solventum Corporation | $40.35 | 2025 | Activ.A.C. |
| Amgen INC. | $39.29 | 2025 | Krystexxa |
| Treace Medical Concepts, INC. | $28.51 | 2024 | |
| Reprise Biomedical, INC. | $23.19 | 2024 | Miro3d |
| Mimedx Group, INC. | $17.61 | 2024 | |
| Averitas Pharma INC. | $16.86 | 2025 | Qutenza |
| Hartmann USA, INC. | $16.54 | 2025 | Zetuvit Plus 10x10 P10 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nelson Negron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.